Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.69 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.59 |
| ▸ | NAAA | Q02083 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11035774 | 1.00 | EPHX2 (0.69) | EPHX2EPHX1ALDH1A1HTTKEAP1 | |
| SCHEMBL11260446 | 1.00 | EPHX2 (0.69) | EPHX2EPHX1ALDH1A1HTTKEAP1 | |
| SCHEMBL3403502 | 1.00 | EPHX2 (0.69) | EPHX2EPHX1ALDH1A1HTTKEAP1 | |
| SCHEMBL4985255 | 0.98 | EPHX2 (0.71) | EPHX2EPHX1ALDH1A1HTTKEAP1 | |
| SCHEMBL3421197 | 0.93 | EPHX2 (0.73) | EPHX2EPHX1ALDH1A1HTTKEAP1 | |
| SCHEMBL11034979 | 0.92 | EPHX1 (0.68) | EPHX2EPHX1ALDH1A1HTT | |
| SCHEMBL11035964 | 0.92 | EPHX1 (0.68) | EPHX2EPHX1ALDH1A1HTT | |
| SCHEMBL6436358 | 0.92 | EPHX2 (0.80) | EPHX2EPHX1KEAP1NFE2L2SMN1; SMN2 | |
| SCHEMBL6438376 | 0.92 | EPHX2 (0.80) | EPHX2EPHX1KEAP1NFE2L2SMN1; SMN2 | |
| SCHEMBL6436792 | 0.92 | EPHX2 (0.80) | EPHX2EPHX1KEAP1NFE2L2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643397-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-21 | — | — | US | disclosed |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-10-25 | — | — | US | disclosed |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2037922-B9 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-10-13 | — | — | US | disclosed |
| US-20150315157-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-11-05 | — | — | US | disclosed |
| EP-2037922-B1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8557834-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-8324208-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-05-06 | — | — | US | disclosed |
| EP-2037922-A2 | PROLYL HYDROXYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007150011-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643397-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | EPHX2 902/4885EPHX1 635/4885ALDH1A1 242/4885 |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EPHX2 902/4885EPHX1 635/4885ALDH1A1 242/4885 |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | EPHX2 893/4885EPHX1 635/4885ALDH1A1 217/4885 |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | EPHX2 902/4885EPHX1 635/4885ALDH1A1 242/4885 |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | EPHX2 902/4885EPHX1 635/4885ALDH1A1 242/4885 |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EPHX2 902/4885EPHX1 635/4885ALDH1A1 242/4885 |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EPHX2 902/4885EPHX1 635/4885ALDH1A1 242/4885 |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | EPHX2 902/4885EPHX1 635/4885ALDH1A1 242/4885 |
| US-20150315157-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | EPHX2 902/4885EPHX1 635/4885ALDH1A1 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.